MATTHEW NACCARATO: Open Payments
NPI 1790403822 · COEUR D ALENE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$402 in 13 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $1,702 · 2025 $402
Food & beverage: $266Education: $136
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 2 | $136 |
| Sumitomo Pharma America, Inc. | 3 | $80 |
| Stryker Corporation | 2 | $40 |
| ACCORD HEALTHCARE, INC. | 2 | $36 |
| Dendreon Pharmaceuticals LLC | 1 | $30 |
| Endo USA, Inc. | 1 | $29 |
| AstraZeneca Pharmaceuticals LP | 1 | $27 |
| Ferring Pharmaceuticals Inc. | 1 | $24 |
Products named: GEMTESA, Camcevi, PROVENGE, AVEED, ADSTILADRIN, TRIATHLON, MAKO.
Industry payments across ID — which companies pay providers there.
